Literature DB >> 11463602

Chronic hypoxia induces constitutive p38 mitogen-activated protein kinase activity that correlates with enhanced cellular proliferation in fibroblasts from rat pulmonary but not systemic arteries.

D J Welsh1, A J Peacock, M MacLean, M Harnett.   

Abstract

Pulmonary hypertension occurs commonly in patients with chronic hypoxic lung disease and is characterized by the remodeling of the pulmonary artery walls. The molecular mechanisms underlying such remodeling are unknown but we have recently shown that the stress-activated (Jnk and p38) mitogen-activated protein (MAP) kinases are activated in pulmonary artery fibroblasts following acute hypoxia. We now show that Erk and p38 MAP kinases are constitutively activated in fibroblasts derived from the remodeled pulmonary, but not the systemic circulation from rats exposed to chronically hypoxic conditions. Moreover, we find that such fibroblasts show sustained enhanced proliferative capacities relative to pulmonary artery fibroblasts derived from normoxic rats or to aortic fibroblasts from either normoxic or hypoxic rats. Finally, abrogation of p38, but not Erk MAP kinase activity by use of specific inhibitors, prevents the enhanced proliferative capacity exhibited by pulmonary artery fibroblasts. Taken together, these data suggest that enhanced p38 MAP kinase activity provides a molecular mechanism to explain the proliferation of pulmonary artery fibroblasts required for remodeling of the pulmonary vasculature.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11463602     DOI: 10.1164/ajrccm.164.2.2008054

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  23 in total

1.  Schistosomiasis-induced experimental pulmonary hypertension: role of interleukin-13 signaling.

Authors:  Brian B Graham; Margaret M Mentink-Kane; Hazim El-Haddad; Shawn Purnell; Li Zhang; Ari Zaiman; Elizabeth F Redente; David W H Riches; Paul M Hassoun; Angela Bandeira; Hunter C Champion; Ghazwan Butrous; Thomas A Wynn; Rubin M Tuder
Journal:  Am J Pathol       Date:  2010-07-29       Impact factor: 4.307

2.  Hypoxia induces unique proliferative response in adventitial fibroblasts by activating PDGFβ receptor-JNK1 signalling.

Authors:  Evgeniy Panzhinskiy; W Michael Zawada; Kurt R Stenmark; Mita Das
Journal:  Cardiovasc Res       Date:  2012-06-26       Impact factor: 10.787

3.  Serotonin drives the activation of pulmonary artery adventitial fibroblasts and TGF-β1/Smad3-mediated fibrotic responses through 5-HT(2A) receptors.

Authors:  Chunyan Chen; Xinyuan Han; Fenling Fan; Ya Liu; Tingzhong Wang; Juanjuan Wang; Peijing Hu; Aiqun Ma; Hongyan Tian
Journal:  Mol Cell Biochem       Date:  2014-09-04       Impact factor: 3.396

4.  Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction.

Authors:  Roshan P Weerackody; David J Welsh; Roger M Wadsworth; Andrew J Peacock
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-02-06       Impact factor: 4.733

Review 5.  Pulmonary hypertension: therapeutic targets within the serotonin system.

Authors:  Y Dempsie; M R MacLean
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

6.  Chronic hypoxia increases pressure-dependent myogenic tone of the uterine artery in pregnant sheep: role of ERK/PKC pathway.

Authors:  Katherine Chang; Daliao Xiao; Xiaohui Huang; Lawrence D Longo; Lubo Zhang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-04-17       Impact factor: 4.733

7.  A novel p38 mitogen-activated protein kinase/Elk-1 transcription factor-dependent molecular mechanism underlying abnormal endothelial cell proliferation in plexogenic pulmonary arterial hypertension.

Authors:  Monal Patel; Dan Predescu; Rajive Tandon; Cristina Bardita; Jennifer Pogoriler; Sangeeta Bhorade; Minhua Wang; Suzy Comhair; Anna Ryan Hemnes; Anna Ryan-Hemnes; Jiwang Chen; Roberto Machado; Aliya Husain; Serpil Erzurum; Sanda Predescu
Journal:  J Biol Chem       Date:  2013-07-26       Impact factor: 5.157

8.  Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension.

Authors:  C Agard; M Rolli-Derkinderen; E Dumas-de-La-Roque; M Rio; C Sagan; J P Savineau; G Loirand; P Pacaud
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

Review 9.  Novel signaling pathways in pulmonary arterial hypertension (2015 Grover Conference Series).

Authors:  Keytam S Awad; James D West; Vinicio de Jesus Perez; Margaret MacLean
Journal:  Pulm Circ       Date:  2016-09       Impact factor: 3.017

Review 10.  The adventitia: Essential role in pulmonary vascular remodeling.

Authors:  Kurt R Stenmark; Eva Nozik-Grayck; Evgenia Gerasimovskaya; Adil Anwar; Min Li; Suzette Riddle; Maria Frid
Journal:  Compr Physiol       Date:  2011-01       Impact factor: 9.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.